Ibex Japan Joins OIST Startup Accelerator As External Partner
The partner role puts an investor-side gatekeeper inside a publicly funded deep tech pipeline, which matters most for the four selected startups that must convert research into fundable businesses before February 2027.
Reporting from 1 source: ASCII.jp.
Ibex Japan will join the OIST Innovation Startup Accelerator 2026 as an external partner, running an investment readiness program at the Okinawa Institute of Science and Technology Graduate University from late October. Four companies were selected: MINORICA, Castomize Technologies, Myimmune Corporation, and KeKatu. The roughly 10-month program ends with a showcase and graduation pitch in February 2027.
Ibex Japan will work with the selected companies from the investor side rather than the research side. Its investment readiness program starts at OIST in late October, identifying gaps in each company's business and technology and building fundraising milestones, an investment thesis, due diligence materials, and a data room.
A three-day bootcamp runs November 1 to 3, covering problem, market, technology, business model, traction, and financials, with pitch training ahead of dialogue with investors at OIST-Lifetime Startup Elevate 2026. Ibex stays on afterward through follow-up, due diligence, data room upgrades, and term sheet and fundraising strategy work, ahead of the February 2027 showcase and graduation pitch.
- MINORICA Co., Ltd.: AgriTech and FoodTech startup working on plant photosynthetic capacity and crop yield under heat stress, with demonstrations in Southeast Asia
- Castomize Technologies: Singapore-based MedTech startup developing reusable medical casts using smart materials and 4D printing
- Myimmune Corporation: Biotech startup developing the AI antibody discovery platform AbSapien, with research use at Osaka University
- KeKatu: Circular Economy startup converting industrial waste and biomass into high-value-added soil materials, with MVP development in Okinawa
Synthesized by Yomimono from the 1 cited source below, including Japanese-language reporting where cited, then editorially reviewed before publishing.